The NHLBI convened a Working Group (WG) Meeting on Guided Antithrombotic Therapy on June 30 and July 1, 2011, at the National Institutes of Health in Bethesda, MD. The WG included cardiologists, hematologists, interventionalists, clinical trialists, genetic epidemiologists, basic scientists, and other stakeholders to address 1) the development and clinical use of anticoagulant and antiplatelet medications and 2) to provide recommendations and develop a research agenda for the NHLBI to enhance understanding and effectiveness of antithrombotic therapy, and to advance guided antithrombotic therapy.
The specific goals of the WG were:
The agenda covered by the WG included a) coagulation, platelet activation and aggregation, and antithrombotic therapy; b) issues surrounding antithrombotic therapy failure ? how to define it, how to predict and diagnose it, available tests and how to optimize them; c) the factors that affect the efficacy, safety, and predictability of antithrombotic therapies; d) how to optimize antithrombotic therapy, improve upon present interventions, and individually tailor therapy to increase efficacy and safety and to avoid failure; and e) the clinical applicability and cost-effectiveness of individually tailored antithrombotic therapy based on functional and genetic testing. The WG characterized and discussed challenges for guided antithrombotic therapy in four domains: therapeutic strategies, antithrombotic metrics, pharmacology and pharmacogenetics, and stakeholders? roles. Overall, the WG sought to identify and prioritize the most pressing clinical needs to focus future research and translational efforts.
The WG identified a set of research and policy priorities related to guided antithrombotic therapy.
The Working Group plans to write a detailed summary of the meeting for publication in an appropriate peer-reviewed journal.
Division of Cardiovascular Sciences, Division of Blood Diseases and Resources, NHLBI
Valentin Fuster, MD, PhD, Mount Sinai School of Medicine
Last Updated September 2011